EUVIMED · CrossrefJournal
BioDrugs
ISSN 1173-8804 · Springer Science and Business Media LLC
Latest articles
Antisense Oligonucleotides as Quantitative Modulators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR): A Threshold-Based Therapeutic Framework for Class I and Class V CFTR Mutations
The Effect of Anti-drug Antibodies on the Bioavailability of Alglucosidase Alfa in Classic Infantile Pompe Disease
From Reflection to Implementation: Tailored Clinical Development of a Pembrolizumab Biosimilar Candidate
Biologic Therapies for Alleviating Neurodegeneration in Lysosomal Storage Diseases
Biosimilars: A Virtuous Cycle of Sustainability and Innovation
HLX11: A Pertuzumab Biosimilar
Beyond the Prevention of Anti-drug Antibody Formation with Uricase Therapy: Mechanistic Roles of DMARDs in Modifying Gout Flare Risk
Incidence and Risk Factors of Treatment-Emergent Eczematous Reactions in Patients with Psoriasis Treated with Biologics: A Systematic Review and Meta-Analysis
Sustained Efficacy and Safety of Mirikizumab Through 152 Weeks in Chinese Patients with Moderately to Severely Active Crohn’s Disease: A Subpopulation Analysis of the VIVID-1 and VIVID-2 Phase 3 Trials
Plant-Based Systems for Producing Therapeutic Proteins: Current Status and Future Prospects
Correction: Monoclonal Antibodies Targeting Bacterial Infections: A Broad Review of the Field
IL-6 Blockade for Antibody-Mediated Transplant Rejection: What Does the Evidence Say?
Impact of Anti-drug Antibodies in Patients with Fabry Disease under Enzyme Replacement Therapy: Long-Term Outcomes
Risk of Major Cardiovascular Events in Patients with Psoriasis, Psoriatic Arthritis, and/or Other Forms of Spondyloarthritis: A Cohort of 72,291 Biologic New Users
Home Infusion With Recombinant Human α-Glucosidase in Children With Pompe Disease: The Dutch Experience Over 20 Years Across the Spectrum From Classic Infantile to Late-Onset Phenotypes
Targeting CD38 Across Autoimmune and Plasma Cell–Driven Immune-Mediated Diseases: Rationale, Clinical Evidence, and Emerging Therapeutic Landscape
Mirikizumab as Induction and Maintenance Therapy in Chinese Patients with Ulcerative Colitis: A Subpopulation Analysis of the Randomized, Global Phase 3 LUCENT-1 and LUCENT-2 Trials
Recombinant Protein Drugs: A 2025 Update
Balancing Efficacy and Safety in Multiple Myeloma Patients Receiving B cell Maturation Antigen–Directed CAR T-Cell Therapy
Understanding the Therapeutic Potential of PD-1 Agonism in Inflammatory and Autoimmune Disorders
Monoclonal Antibodies Targeting Bacterial Infections: A Broad Review of the Field
An Overview and Trend Analysis of Biosimilar Approvals in China
Biologics in Kidney Transplantation: Why and How Should We Personalize Their Dosage?
Impact of Repeated Antigen Exposure on Humoral Tolerance: Antidrug Antibodies After Single-Dose Versus Multi-dose Adalimumab
Programmed Cell Death Protein 1-Interleukin-2 Bispecific Agents for Cancer Therapy
Advanced Combination Therapy in Inflammatory Bowel Disease: What Does the Future Hold?
In Vivo T-Cell Engineering: Revolution in Delivery Strategies and Clinical Translation
Effectiveness of Lebrikizumab Treatment for Patients with Atopic Dermatitis Switched from Dupilumab or Tralokinumab: A 48-Week Real-World Retrospective Study
The Market for Monoclonal Antibodies: Trends, Challenges, and Opportunities
Progress in Designing Cytokine Antagonist Antibodies for Cancer Therapy
EUVIMED